In children and adolescents, the pharmacodynamics of high-dose busulfan is dependent on the second alkylating agent used in the combined regimen (melphalan or thiotepa)

@article{Bouligand2003InCA,
  title={In children and adolescents, the pharmacodynamics of high-dose busulfan is dependent on the second alkylating agent used in the combined regimen (melphalan or thiotepa)},
  author={J{\'e}r{\^o}me Bouligand and Isabelle Boland and Dominique Valteau-Couanet and Alain Deroussent and Chantale Kalifa and Olivier Hartmann and Gilles Vassal},
  journal={Bone Marrow Transplantation},
  year={2003},
  volume={32},
  pages={979-986}
}
Summary:A strong relationship has been demonstrated between high systemic exposure to busulfan and the occurrence of hepatic veno-occlusive disease (HVOD) after a busulfan–cyclophosphamide regimen (BU CY). We report a prospective study aimed at exploring the pharmacodynamics of high-dose busulfan combined with either melphalan (BU MEL) or thiotepa (BU TTP) followed by autologous stem cell transplantation in children and adolescents with a malignant solid tumor. Busulfan was given orally at a… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 16 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 50 references

Similar Papers

Loading similar papers…